RARE - Ultragenyx Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (5Y Monthly) 2.14
52-Week Change 319.02%
S&P500 52-Week Change 325.98%
52 Week High 374.50
52 Week Low 335.41
50-Day Moving Average 346.13
200-Day Moving Average 347.79

Share Statistics

Avg Vol (3 month) 3569.01k
Avg Vol (10 day) 31.29M
Shares Outstanding 557.77M
Float 54.35M
% Held by Insiders 15.95%
% Held by Institutions 1101.64%
Shares Short (Dec 30, 2019) 46.5M
Short Ratio (Dec 30, 2019) 412.69
Short % of Float (Dec 30, 2019) 415.41%
Short % of Shares Outstanding (Dec 30, 2019) 411.25%
Shares Short (prior month Nov 28, 2019) 46.87M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:3
Last Split Date 3Jan 16, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin 0.00%
Operating Margin (ttm)-497.81%

Management Effectiveness

Return on Assets (ttm)-31.92%
Return on Equity (ttm)-57.09%

Income Statement

Revenue (ttm)84.38M
Revenue Per Share (ttm)1.54
Quarterly Revenue Growth (yoy)119.30%
Gross Profit (ttm)-243.65M
EBITDA -410.75M
Net Income Avi to Common (ttm)-396.75M
Diluted EPS (ttm)-7.24
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)527.06M
Total Cash Per Share (mrq)9.12
Total Debt (mrq)38.5M
Total Debt/Equity (mrq)5.29
Current Ratio (mrq)6.79
Book Value Per Share (mrq)12.59

Cash Flow Statement

Operating Cash Flow (ttm)-329.2M
Levered Free Cash Flow (ttm)-190.04M